Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYOFIX-O is a fixed-dose combination antibiotic product containing cefixime and ofloxacin, developed and marketed by Sycon Healthcare. Cefixime is a third-generation cephalosporin that exerts its bactericidal effect by binding to and inhibiting penicillin-binding proteins (PBPs), thereby disrupting bacterial cell wall synthesis. Ofloxacin is a second-generation fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This combination is particularly effective against a broad spectrum of Gram-positive and Gram-negative bacteria and is frequently prescribed for the treatment of typhoid fever (enteric fever), complicated urinary tract infections, and respiratory tract infections where resistance to monotherapy is suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefixime + ofloxacin (Sycon Healthcare).